




# Semiconductor Conference

Wednesday, 7 May 2025



9:00AM **Pitt Street Research welcome**

9:05AM **Bell Potter welcome**

9:10AM **Keynote Speaker - Adisyn (AI1)**

9:40AM **BrainChip (BRN)**

10:05AM **Adisyn (AI1)**

10:30AM **Archer Materials (AXE)**

11:15AM **Alpha HPA (A4N)**

11:40AM **Nanoveu**

12:05PM **4DS Memory (4DS)**

1:15PM **BluGlass (BLG)**

1:40PM **Diraq**

2:05PM **Weebit Nano (WBT)**


2:30PM **Wrap up**

# Introduction to Bell Potter Securities

Australia's largest dedicated mid-market, full-service broker with a leading ECM franchise and unrivalled distribution capabilities

## 1 Leading Corporate Finance and ECM Franchise

- Dedicated focus on emerging companies
- #2** by value, completing ~\$8.4 billion<sup>1</sup> in equity raisings across IPOs and secondary offerings over the last 5 years (excl. global investment banks)
- #2** by volume, completing 418<sup>1</sup> ECM transactions over the same period



## 2 Partnership Approach to its Clients

- Our commitment to our clients is demonstrated through a strong track record of supporting 'house stocks' in the after-market through ongoing research, and marketing
- Bell Potter has committed its 'whole-of-firm' approach to DroneShield by:
  - ✓ Initiating on the stock in Sep-22 and released 27 reports since;
  - ✓ Hosted every results roadshow;
  - ✓ Successfully acted as Corporate Adviser, Joint Lead Manager and Joint Underwriter to capital raisings totaling ~\$275m since Feb-23 to accelerate growth in R&D; and
  - ✓ Received ~\$53m in Bell Potter retail bids across all capital raisings.

**DRONESHIELD**  
 \$40.3m Placement & SPP (Feb-23)  
 \$115.5m Placement & SPP (Apr-24)  
 \$120m Placement (Jul-24)

## 3 Unrivalled Distribution Capabilities

- Global distribution with an institutional sales presence in Australia, Asia, UK / Europe and North America, broking ASX-listed stocks
- Dedicated emerging companies capability targeting domestic and international institutions
- Powerful retail network with ~300 retail advisers across 11 Australian offices, servicing ~600,000 clients with ~A\$85.8 billion in Funds Under Advice
- Client base includes ~38,000 sophisticated and professional investors and family offices



**BELL POTTER**

## 4 Top Ranking Research


- Research is one of the cornerstones of our business, a truly broad and outstanding research offering
- Leading small cap and emerging company sector voice in Australia – leading retail network provides to a large reader base
- 20 emerging companies, with analysts covering more than 180 companies



**EOS**

**DRONESHIELD**

**IPERIONX**






# Market leader for mid-market capital raisings over the last 5 years

Bell Potter has been a market leader by deal value, excluding the global investment banks

## IPOs and Secondaries by Broker (A\$bn, CY20-24)<sup>1,2</sup>



Alpha HPA

**\$265.0m**

Placement 21' (\$50m)  
Placement 23' (\$40m)  
Placement 24' (\$175m)

IPERIONX

**\$176.0m**

Placement 23' (\$26m)  
Placement 24' (\$50m)  
Placement 24' (\$100m)

DRONESHIELD

**\$275.8m**

Placement 23' (\$40m)  
Placement 24' (\$116m)  
Placement 24' (\$120m)

PROPEL FUNERAL PARTNERS

**\$272.0m**

IPO 17' (\$132m)  
Placement 21' (\$60m)  
Placement 24' (\$80m)

ebr  
SYSTEMS

**\$195.0m**

IPO 21' (\$110m)  
Placement 23' (\$35m)  
Placement & ANREO 24' (\$50m)

immutep  
LACI IMMUNOTHERAPY

**\$292.0m**

Placement 19' (\$10m)  
Placement 20' (\$30m)  
Placement 20' (\$12m)  
Placement 21' (\$60m)  
Placement & ANREO 23' (\$80m)  
Placement & ANREO 24' (\$100m)

CLARITY  
PHARMACEUTICALS

**\$213.0m**

IPO 21' (\$92m)  
Placement & ANREO 24' (\$121m)

NICKEL  
INDUSTRIES

**\$1,819.0m**

IPO 18' (\$200m)  
Placement 19' (\$55m)  
ANREO 20' (\$231m)  
ANREO 20' (\$364m)  
Placement 22' (\$296m)  
Placement 23' (\$673m)

Liontown

**\$896.1m**

Placement 19' (\$17m)  
Placement 20' (\$12m)  
Placement 21' (\$52m)  
Placement 21' (\$450m)  
Placement 23' (\$365m)

mesoblast

**\$455.0m**

Rights 17' (\$51m)  
Placement 19' (\$75m)  
Placement 20' (\$137m)  
Placement 22' (\$65m)  
Placement 23' (\$65m)  
Placement & ANREO 23' (\$60m)  
Placement 25' (\$260m)

chalice

**\$300.1m**

Placement 20' (\$30m)  
Placement 20' (\$100m)  
Placement 22' (\$100m)  
Placement 23' (\$70m)

ipd group

**\$105.0m**

IPO 21' (\$40m)  
Placement & ANREO 23' (\$65m)

FRONTIER  
DIGITAL VENTURES

**\$263.0m**

IPO 16' (\$30m)  
Placement & ANREO 18' (\$14m)  
Placement & ANREO 20' (\$100m)  
Block Trade 21' (\$69m)  
Placement 21' (\$35m)  
Placement 23' (\$15m)

IMUGENE

**\$277.0m**

Placement 21' (\$95m)  
Block Trade 21' (\$37m)  
Placement 22' (\$80m)  
Placement 23' (\$65m)

Aeris  
RESOURCES

**\$237.0m**

Placement 20' (\$40m)  
Placement 21' (\$50m)  
Placement & ANREO 22' (\$117m)  
Placement & ANREO 23' (\$30m)

Life360

**\$520.4m**

Series-D 18' (\$45m)  
IPO 19' (\$145m)  
Placement & ANREO 21' (\$280m)  
Placement 22' (\$50m)